Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Vadims Kovada und 15 weiteren Autor:innen. Beteiligte Einrichtung: Latvian Institute of Organic Synthesis, Riga LV-1006, Latvia. Hauptthemen laut MEDLINE: Antimalarials, Peptidomimetics. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, European Regional Development Fund.
Abstract (Originalsprache)
The Plasmodium falciparum aspartic protease plasmepsin X (PMX) is essential for the egress of invasive merozoite forms of the parasite. PMX has therefore emerged as a new potential antimalarial target. Building on peptidic amino alcohols originating from a phenotypic screening hit, we have here developed a series of macrocyclic analogues as PMX inhibitors. Incorporation of an extended linker between the S1 phenyl group and S3 amide led to a lead compound that displayed a 10-fold improved PMX inhibitory potency and a 3-fold improved half-life in microsomal stability assays compared to the acyclic analogue. The lead compound was also the most potent of the new macrocyclic compounds in in vitro parasite growth inhibition. Inhibitor 7k cleared blood-stage P. falciparum in a dose-dependent manner when administered orally to infected humanized mice. Consequently, lead compound 7k represents a promising orally bioavailable molecule for further development as a PMX-targeting antimalarial drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Latvian Institute of Organic Synthesis, Riga LV-1006, Latvia.
- Malaria Biochemistry Laboratory, The Francis Crick Institute, London NW1 1AT, United Kingdom.
- The Art of Discovery SL, Biscay Science and Technology Park, Derio, 48160 Bizkaia, Basque Country, Spain.
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, United Kingdom.
ORCID-Profile: Raitis Bobrovs, Dace Rasina, Edgars Suna, Kristaps Jaudzems, Michael J Blackman, Aigars Jirgensons
Förderung
- Wellcome Trust
- Medical Research Council
- European Regional Development Fund
- Cancer Research UK
- LIOS student grant
- Latvian Investment and Development agency
Zitieren
APA
Kovada, V., Withers-Martinez, C., Bobrovs, R., Ce Rule, H. N., Liepins, E., Grinberga, S., Hackett, F., Collins, C. R., Kreicberga, A., Jiménez-Díaz, M. B., Angulo-Barturen, I., Rasina, D., Suna, E., Jaudzems, K., Blackman, M. J., & Jirgensons, A. (2023). Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00812
Vancouver
Kovada V, Withers-Martinez C, Bobrovs R, Ce Rule HN, Liepins E, Grinberga S, et al. Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00812
BibTeX
@article{Kovada2023,
author = {Kovada, Vadims and Withers-Martinez, Chrislaine and Bobrovs, Raitis and Ce Rule, Hele Na and Liepins, Edgars and Grinberga, Solveiga and Hackett, Fiona and Collins, Christine R and Kreicberga, Agrita and Jiménez-Díaz, María Belén and Angulo-Barturen, Iñigo and Rasina, Dace and Suna, Edgars and Jaudzems, Kristaps and Blackman, Michael J and Jirgensons, Aigars},
title = {Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00812}
}
EUVIMED